The world’s longest-lasting continuous glucose monitor moves closer to European market approval. ...
The collaboration aims to drive long-term brain monitoring and neurostimulation innovations into clinical applications....
Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation ...
With a strategic separation, BD is creating a pure-play MedTech leader and a focused Life Sciences and Diagnostics entity, driving enhanced investment, innovation, and market impact....
The collaboration aims to promote virtual reality solutions for enhancing senior care and well-being....
Simultaneous approval of AI solutions for diagnosing sleep disorders and digital therapeutics for insomnia...
Strategic move aims to accelerate advancements in cancer detection and drug development....
World’s first pin-less, image-less solution for precise acetabular cup positioning in anterior hip arthroplasty....
Asia-Pacific region houses some of Galderma’s fastest growing markets, where sales have fueled a strong performance. There have been multiple successes in the region in 2024 for the Swiss pharmaceutical firm, with a number of important product launches, such as Restylane VOLYME in China, Restylane EYELIGHT in Korea and Alastin in Australia. More recently, Relfydess (RelabotulinumtoxinA) was approved in Australia and Sculptra - which celebrated its 25th launch anniversary this year - was approved...
The enhanced system now supports multiple languages, improving accessibility for global drug screening operations....
